Genfit SA GNFT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
-
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
-
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Trading Information
- Previous Close Price
- €5.17
- Day Range
- €5.22–5.59
- 52-Week Range
- €2.84–5.79
- Bid/Ask
- €5.40 / €5.47
- Market Cap
- €270.99 Mil
- Volume/Avg
- 783,111 / 199,452
Key Statistics
- Price/Earnings (Normalized)
- 17.04
- Price/Sales
- 3.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 167
- Website
- https://www.genfit.com
Comparables
Valuation
|
Metric
|
GNFT
|
ALSEN
|
ABVX
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.04 | — | — |
Price/Book Value | 2.65 | 2.73 | 3.27 |
Price/Sales | 3.74 | 32.08 | — |
Price/Cash Flow | 11.85 | — | — |
Price/Earnings
GNFT
ALSEN
ABVX
Financial Strength
|
Metric
|
GNFT
|
ALSEN
|
ABVX
|
|---|---|---|---|
Quick Ratio | 3.64 | 6.77 | 4.00 |
Current Ratio | 3.74 | 6.92 | 4.08 |
Interest Coverage | 5.34 | −137.96 | −9.89 |
Quick Ratio
GNFT
ALSEN
ABVX
Profitability
|
Metric
|
GNFT
|
ALSEN
|
ABVX
|
|---|---|---|---|
Return on Assets (Normalized) | 12.22% | −39.65% | −70.24% |
Return on Equity (Normalized) | 28.66% | −54.99% | −142.04% |
Return on Invested Capital (Normalized) | 17.01% | −54.41% | −89.54% |
Return on Assets
GNFT
ALSEN
ABVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vzvzbslwl | Qwmtd | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ktmxmtzn | Lbbbfp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hxndvvjg | Gjknx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cllknxlb | Xgszfk | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Trgsgmjc | Xpxb | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cxpdbxnn | Txt | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hjcnzmll | Wbql | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kdhslmx | Gmvx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mxztndmc | Glwfm | $13.4 Bil | |||
| Incyte Corp
INCY
| Rfqlplsm | Wljbn | $12.7 Bil |
United States